Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other Accumulated Expenses: 2019-2021

Historic Other Accumulated Expenses for C4 Therapeutics (CCCC) over the last 3 years, with Dec 2021 value amounting to $413,000.

  • C4 Therapeutics' Other Accumulated Expenses fell 65.16% to $309,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $309,000, marking a year-over-year decrease of 65.16%. This contributed to the annual value of $413,000 for FY2021, which is 11.94% down from last year.
  • According to the latest figures from FY2021, C4 Therapeutics' Other Accumulated Expenses is $413,000, which was down 11.94% from $469,000 recorded in FY2020.
  • C4 Therapeutics' 5-year Other Accumulated Expenses high stood at $469,000 for FY2020, and its period low was $280,000 during FY2019.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $413,000 (2021), whereas its average is $387,333.
  • In the last 5 years, C4 Therapeutics' Other Accumulated Expenses skyrocketed by 67.50% in 2020 and then declined by 11.94% in 2021.
  • C4 Therapeutics' Other Accumulated Expenses (Yearly) stood at $280,000 in 2019, then spiked by 67.50% to $469,000 in 2020, then dropped by 11.94% to $413,000 in 2021.